Trial · NCT07465029
A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain
NCT07465029, Active not recruiting, Bristol-Myers Squibb
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain. Trials, record NCT07465029. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07465029
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain
- NCT number
- NCT07465029
- Status
- Active not recruiting
- Enrollment
- 1,300 participants, estimated
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Lower-risk Myelodysplastic Syndromes (TD LR-MDS)
- Interventions
- Erythropoiesis-stimulating agents (ESAs), Luspatercept, Lenalidomide, Hypomethylating agents (HMAs), Reb blood cell transfusion
- First posted
- 2026-03-11
- Last updated
- 2026-10-01
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) | Up to 5-years | |
| Primary | Prevalence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) | Up to 5-years | |
| Secondary | Proportion of participants receiving each first-line treatment category | Up to 5-years | Treatment categories include: * Erythropoiesis-stimulating agents (ESA) * Luspateracept * Hypomethylating agents (HMAs) * Lenalidomide * Conservative management (red-blood cell (RBC) transfusions without disease modifying therapy) |
| Secondary | Proportion of participants by treatment category at each line of therapy | Up to 5-years | Treatment category received at each line of therapy (first line, second line, third line and beyond), categorized as erythropoiesis-stimulating agents (ESA), luspatercept, hypomethylating agents (HMA), lenalidomide, or conservative management (red blood cell transfusions without disease-modifying therapy). Treatment sequences will be derived from retrospective medical chart abstraction of documented treatment start and stop dates. |
| Secondary | Treatment duration (time from initiation to discontinuation) of first-line treatment | Up to 5-years | |
| Secondary | Defined as number of RBC units received per participant per 8-weeks | Up to 5-years | |
| Secondary | Number and Rate of Healthcare Resource Utilization Events | Up to 5-years | Healthcare resource utilization events, including primary care visits, specialist visits, outpatient visits all-cause hospitalizations, transfusion-related hospitalizations, general laboratory tests, number of prescriptions related to transfusion-dependent lower-risk myelodysplastic syndromes, red blood cell transfusions, use of concomitant medicines related to other comorbidities as documented in participant medical records. |
| Secondary | Number of participants that achieve hematologic improvement-erythroid (HI-E) | Up to 5-years | |
| Secondary | Number of participants that achieve red-blood cell (RBC) transfusion independence (TI) | Up to 5-years | |
| Secondary | Number of participants that experience a change in transfusion burden (change in number of red-blood cell units received per 8-weeks) | Up to 5-years |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07465029
GET https://conductscience.org/api/trials/v1/NCT07465029/registered?page=2